Clinical Trials Logo

Clinical Trial Summary

To describe the safety, tolerability and immunogenicity of pneumovax 23 (V110) in healthy adults in India.


Clinical Trial Description

This was an open-label non-randomized study to assess the safety and immunogenicity of PNEUMOVAXTM 23 in healthy adults in India. The participants enrolled in this study were healthy Indian adults, 50 years of age or older, with no prior history of having received a pneumococcal vaccination (14-valent or 23-valent) and no prior history of Pneumococcal disease. All participants enrolled in the study received one 0.5 mL dose of PNEUMOVAXTM 23 by intramuscular (deltoid) injection on Day 1. Serum samples were obtained prior to vaccination on Day 1 and on Day 28 (+/-7 days) postvaccination. The duration of participation for each participant was approximately one month, with the study completion at the Day 28 postvaccination bleed and return of the Vaccination Report Card (VRC). Enrollment was completed within approximately 2 months. The last postvaccination blood sample was collected within 3 months of study initiation. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00496093
Study type Interventional
Source Merck Sharp & Dohme Corp.
Contact
Status Completed
Phase Phase 3
Start date October 2005
Completion date January 2006

See also
  Status Clinical Trial Phase
Completed NCT02463539 - Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis N/A
Completed NCT03095326 - Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia Phase 4
Completed NCT02260882 - Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902) Phase 4
Completed NCT02572635 - A Phase I Study to Evaluate the Safety and Immunogenicity of PnuBioVax Phase 1
Completed NCT01654263 - A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine Phase 2
Completed NCT01531322 - A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects Phase 1
Completed NCT02062281 - Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults Phase 4
Completed NCT00133549 - 9-valent CRM 197 Pneumococcal Phase 2
Completed NCT03467984 - A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants Phase 2
Active, not recruiting NCT03489018 - The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants Phase 4
Recruiting NCT02463578 - Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis N/A
Completed NCT00535730 - ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED) Phase 3
Completed NCT02558751 - Pneumonia Vaccine in Aging HIV Positive Individuals Phase 0
Completed NCT02515240 - Immune Response to Pneumococcal Vaccination in HIV Infected Individuals Phase 0
Completed NCT00560950 - Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007) Phase 3
Completed NCT05425732 - Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3) Phase 3
Completed NCT03619252 - Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Phase 4
Not yet recruiting NCT03549208 - A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Phase 1
Not yet recruiting NCT03341195 - Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan N/A
Recruiting NCT06177912 - A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) Phase 3